EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Whether to hold and what to measure: perioperative euglycemic ketoacidosis in patients taking SGLT2 inhibitors

Eun Ji Park, Jeong-Min Hong

Anesthesia and Pain Medicine · 31.10.2026 · 21 (4) · 465-485

DOI: 10.17085/apm.26812 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anesthesia and Pain Medicine, erschienen am 31.10.2026. Verfasst von Eun Ji Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Pain Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pusan National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used for type 2 diabetes, heart failure, and chronic kidney disease, including in patients without diabetes. Their ketogenic effects may be amplified perioperatively by fasting, surgical stress, and volume loss, resulting in ketoacidosis without marked hyperglycemia. Reported frequencies depend on ascertainment. Where ketones were measured against a diagnostic threshold, cohorts reported 0–1.8% in non-cardiac and mixed populations and 0–15.1% in cardiac surgery; one prospective study using a lower threshold (≥ 0.6 mmol/L) reported a far higher figure, and studies without ketone measurement reported surrogate metabolic-acidosis endpoints of 30–41%. None of these are comparable incidence estimates. Severe and fatal cases have been reported. Because plasma glucose may be normal, diagnosis requires attention to acid–base status and ketones. Quantitative blood β-hydroxybutyrate is preferred when SGLT2 inhibitor (SGLT2i)-associated ketoacidosis is suspected; urine ketone tests may screen when blood testing is unavailable, but a negative result does not exclude it. Perioperative guidance remains inconsistent: some bodies recommend withholding SGLT2i for 3 days (4 days for ertugliflozin), whereas others support risk-stratified continuation in selected patients under specified fasting and dietary conditions. No randomized trial has compared continuation with discontinuation using perioperative ketoacidosis as an endpoint; observational evidence remains limited and conflicting, and ketone thresholds and monitoring intervals lack prospective validation. This review summarizes evidence on recognition, diagnosis, withholding, monitoring, and postoperative restart.

Schlagwörter

Stichwörter der Autor:innen

3-Hydroxybutyric acidAnesthesiaDiabetic ketoacidosisKetone bodiesPerioperative carePoint-of-care testingSodium-glucose transporter 2 inhibitors

Autor:innen und Institutionen

  • Department of Anesthesia and Pain Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea.
  • Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea.

Förderung

  • Pusan National University

Zitieren

APA

Park, E. J., & Hong, J. M. (2026). Whether to hold and what to measure: perioperative euglycemic ketoacidosis in patients taking SGLT2 inhibitors. Anesthesia and Pain Medicine, 21(4), 465-485. https://doi.org/10.17085/apm.26812

Vancouver

Park EJ, Hong JM. Whether to hold and what to measure: perioperative euglycemic ketoacidosis in patients taking SGLT2 inhibitors. Anesthesia and Pain Medicine. 2026;21(4):465-485. doi:10.17085/apm.26812

BibTeX
@article{Park2026,
  author = {Park, Eun Ji and Hong, Jeong-Min},
  title = {Whether to hold and what to measure: perioperative euglycemic ketoacidosis in patients taking SGLT2 inhibitors},
  journal = {Anesthesia and Pain Medicine},
  year = {2026},
  volume = {21},
  number = {4},
  pages = {465--485},
  doi = {10.17085/apm.26812}
}
Kostenlos starten →